Exicure, Inc. (NASDAQ:XCUR) Sees Large Growth in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 506,729 shares, an increase of 7,428.3% from the June 30th total of 6,731 shares. Approximately 16.8% of the company’s stock are sold short. Based on an average daily volume of 2,149,123 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Exicure Stock Up 2.9%

NASDAQ XCUR opened at $1.76 on Friday. The firm has a 50-day moving average price of $2.40 and a two-hundred day moving average price of $3.62. Exicure has a 12-month low of $1.43 and a 12-month high of $9.48. The company has a market capitalization of $11.21 million, a P/E ratio of -1.14 and a beta of 3.61.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings results on Friday, May 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.31.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.